State-of-the-art therapeutics: Hodgkin's lymphoma

Journal of Clinical Oncology

Volumn 23, Issue 26, 2005, Pages 6400-6408

  Connors, Joseph M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADJUVANT THERAPY; ADVANCED CANCER; BLOOD TOXICITY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; EARLY MENOPAUSE; FEMALE INFERTILITY; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE INFERTILITY; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SECOND CANCER; ADULT; COMPARATIVE STUDY; DRUG ADMINISTRATION; FEMALE; HOSPITALIZATION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; RISK ASSESSMENT; SURVIVAL;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HODGKIN DISEASE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 27244442106     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.016     Document Type: Review

References (72)

1. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 7:1630-1636, 1989
2. Bonadonna G, Zucali R, Monfardini S, et al: Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP. Cancer 36:252-259, 1975
3. Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin's disease: International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 339:1506-1514, 1998
4. Krikorian JG, Portlock CS, Rosenberg SA, et al: Hodgkin's disease, stages I and II occurring below the diaphragm. Cancer 43:1866-1871, 1979
5. Carde P, Burgers JM, Henry-Amar M, et al: Clinical stages I and II Hodgkin's disease: A specifically tailored therapy according to prognostic factors. J Clin Oncol 6:239-252, 1988
6. B. Hagenbeek A, Carde P, Noordijk EM, et al: Prognostic factor tailored treatment of early stage Hodgkin's disease: Results from a prospective randomized phase III clinical trial in 762 patients (H7 study). Blood 90:585a, 1997 (suppl 1)
7. Rostock RA, Giangreco A, Wharam MD, et al: CT scan modification in the treatment of mediastinal Hodgkin's disease. Cancer 49:2267-2275, 1982
8. Carde P, Hagenbeek A, Hayat M, et al: Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: The H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 11:2258-2272, 1993
9. Shore T, Nelson N, Weinerman B: A meta-analysis of stages I and II Hodgkin's disease. Cancer 65:1155-1160, 1990
10. Bonfante V, Viviani S, Devizzi L, et al: Ten years experience with ABVD plus radiotherapy: Subtotal nodal (STNI) vs involved field (IFRT) in early-stage Hodgkin's disease. Proc Am Soc Clin Oncol 20:281 a, 2001 (abstr 1120)
11. Klasa RJ, Connors JM, Fairey R, et al: Treatment of early stage Hodgkin's disease: Improved outcome with brief chemotherapy and radiotherapy without staging laparotomy. Ann Oncol 7:21, 1996 (suppl 3)
12. Tesch H, Sieber M, Buffer JU, et al: 2 cycles of ABVD plus radiotherapy is more effective than radiotherapy alone in early stage Hodgkin's disease-Interim analysis of the HD7 trial of the GHSG. Blood 91:485a, 1998 (abstr 2001)
13. Specht L, Gray RG, Clarke MJ, et al: Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: A meta-analysis of 23 randomized trials involving 3,888 patients: International Hodgkin's Disease Collaborative Group. J Clin Oncol 16:830-843, 1998
14. Zittoun R, Audebert A, Hoerni B, et al: Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease. J Clin Oncol 3:207-214, 1985
15. Rosenberg SA, Kaplan HS: The evolution and summary results of the Stanford randomized clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 11:5-22, 1985
16. Horning SJ, Hoppe RT, Hancock SL, et al: Vinblastine, bleomycin, and methotrexate: An effective adjuvant in favorable Hodgkin's disease. J Clin Oncol 6:1822-1831, 1988
17. Josting A, Wiedenmann S, Franklin J, et al: Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: A report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3440-3446, 2003
18. Connors JM: Hodgkin's lymphoma: the hazards of success. J Clin Oncol 21:3388-3390, 2003
19. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al: Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 21:3431-3439, 2003
20. Ng AK, Bernardo MV, Weller E, et al: Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: Long-term risks and risk factors. Blood 100:1989-1996, 2002
21. Ng AK, Bernardo MP, Weller E, et al: Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 20: 2101-2108, 2002
22. Henry-Amar M: Second cancer after the treatment for Hodgkin's disease: A report from the International Database on Hodgkin's Disease. Ann Oncol 3:117-128, 1992 (suppl 4)
23. Cimino G, Biti GP, Anselmo AP, et al; MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease. J Clin Oncol 7: 732-737, 1989
24. Longo DL, Glatstein E, Duffey PL, et al: Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: Seven-year results of a prospective randomized trial. J Clin Oncol 9:906-917, 1991
25. Duggan DB, Petroni GR, Johnson JL, et al: Randomized comparison of ABVD and MOPP/ ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an Intergroup trial. J Clin Oncol 21:607-614, 2003
26. Canellos GP, Anderson JR, Propert KJ, et al: Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478-1484, 1992
27. Meyer RM, Gospodarowicz MK, Connors JM, et al: A randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma. J Clin Oncol 23: 2005, in press
28. Devita VT, Jr., Serpick AA, Carbone PP: Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med 73:881-895, 1970
29. Longo DL, Young RC, Wesley M, et al: Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol 4:1295-1306, 1986
30. Santoro A, Bonadonna G: Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). Cancer Chemother Pharmacol 2:101-105, 1979
31. Viviani S, Santoro A, Ragni G, et al: Gonadal toxicity after combination chemotherapy for Hodgkin's disease: Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 21:601-605, 1985
32. Bonadonna G, Santoro A, Gianni AM, et al: Primary and salvage chemotherapy in advanced Hodgkin's disease: The Milan Cancer Institute experience. Ann Oncol 2 (Suppl 71:9-16, 1991
33. Connors JM: Is cyclic chemotherapy better than standard four-drug chemotherapy for Hodgkin's disease? Yes. Important Adv Oncol 189-195, 1993
34. Loeffler M, Brosteanu O, Hasenclever D, et al: Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease: International Database on Hodgkin's Disease Overview Study Group. J Clin Oncol 16:818-829, 1998
35. Diehl V, Loeffler M, Pfreundschuh M, et al: Further chemotherapy versus low-dose involved-field radiotherapy as consolidation of complete remission after six cycles of alternating chemotherapy in patients with advance Hodgkin's disease: German Hodgkins' Study Group (GHSG). Ann Oncol 6:901-910, 1995
36. Ferme C, Sebban C, Hennequin C, et al: Comparison of chemotherapy to radiotherapy as consolidation of complete or good partial response after six cycles of chemotherapy for patients with advanced Hodgkin's disease: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 trial. Blood 95:2246-2252, 2000
37. Aleman BM, Raemaekers JM, Tirelli U, et al: Involved-field radiotherapy for advanced Hodgkin's lymphoma. N Engl J Med 348:2396-2406, 2003
38. Laskar S, Gupta T, Vimal S, et al: Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: Is there a need? J Clin Oncol 22:62-68, 2004
39. Bartlett NL, Rosenberg SA, Hoppe RT, et al: Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: A preliminary report J Clin Oncol 13:1080-1088, 1995
40. Horning SJ, Hoppe RT, Breslin S, et al: Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: Mature results of a prospective clinical trial. J Clin Oncol 20:630-637, 2002
41. Horning SJ, Hoppe RT, Advani R, et al: Efficacy and late effects of Stanford V chemotherapy and radiotherapy in untreated Hodgkin's disease: Mature data in early and advanced stage patients. Blood 104:92a, 2004 (abstr 308)
42. Diehl V, Franklin J, Pfreundschuh M, et al: Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 348:2386-2395, 2003
43. Diehl V, Brillant C, Franklin J, et al: BEACOPP chemotherapy for advanced Hodgkin's disease: Results of further analyses of the HD9- and HD12- trials of the German Hodgkin Study Group (GHSG). Blood 104:91 a, 2004 (abstr 307)
44. Federico M, Bellei M, Brice P, et al: High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. J Clin Oncol 21:2320-2325, 2003
45. Proctor SJ, Mackie M, Dawson A, et al: A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index: A Scotland and Newcastle Lymphoma Group study (SNLG HD III) Eur J Cancer 38:795-806, 2002
46. Schmitz N, Pfistner B, Sextro M, et al: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359:2065-2071, 2002
47. Linen DC, Winfield D, Goldstone AH, et al: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051-1054, 1993
48. Longo DL, Duffey PL, Young RC, et al: Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210-218, 1992
49. Buzaid AC, Lippman SM, Miller TP: Salvage therapy of advanced Hodgkin's disease: Critical appraisal of curative potential. Am J Med 83:523-532, 1987
50. Bonfante V, Santoro A, Viviani S, et al: Outcome of patients with Hodgkin's disease failing after primary MOPP-ABVD. J Clin Oncol 15:528-534, 1997
51. Roach MD, Brophy N, Cox R, et al: Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease. J Clin Oncol 8:623-629, 1990
52. Mauch P, Tarbell N, Skarin A, et al: Wide-field radiation therapy alone or with chemotherapy for Hodgkin's disease in relapse from combination chemotherapy. J Clin Oncol 5:544-549, 1987
53. Lohri A, Barnett M, Fairey RN, et al: Outcome of treatment of first relapse of Hodgkin's disease after primary chemotherapy: Identification of risk factors from the British Columbia experience 1970 to 1988. Blood 77:2292-2298, 1991
54. Yuen AR, Rosenberg SA, Hoppe RT, et al: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin's disease. Blood 89:814-822, 1997
55. Roach Md, Kapp DS, Rosenberg SA, et al: Radiotherapy with curative intent: An option in selected patients relapsing after chemotherapy for advanced Hodgkin's disease. J Clin Oncol 5:550-555, 1987
56. Anselmo AP, Cavalieri E, Enrici RM, et al: Hodgkin's disease during pregnancy: Diagnostic and therapeutic management. Fetal Diagn Ther 14:102-105, 1999
57. Byram D, Foulstone P: Radiotherapy for Hodgkin's disease in pregnancy Australas Radiol 41:407-408, 1997
58. Franceschi S, Bidoli E, La Vecchia C. Pregnancy and Hodgkin's disease. Int J Cancer 58:465-466, 1994
59. Gobbi PG, Attardo-Parrinello A, Danesino M, et al: Hodgkin's disease and pregnancy Haematologica 69:336-341, 1984
60. Leung JT, Kuan R, Patel V: Radiotherapy for Hodgkin's disease in pregnancy Australas Radiol 40:146-148, 1996
61. Lishner M, Zemlickis D, Degendorfer P, et al: Maternal and foetal outcome following Hodgkin's disease in pregnancy. Br J Cancer 65:114-117, 1992
62. McCann SR, Daly H, Hanratty TD, et al: Hodgkin's disease and pregnancy. Acta Haematol 66:67-68, 1981
63. Nisce LZ, Tome MA, He S, et al: Management of coexisting Hodgkin's disease and pregnancy. Am J Clin Oncol 9:146-151, 1986
64. Tawil E, Mercier JP, Dandavino A: Hodgkin's disease complicating pregnancy. J Can Assoc Radiol 36:133-137, 1985
65. Rapezzi D, Ugolini D, Ferraris AM, et al. Histological subtypes of Hodgkin's disease in the setting of HIV infection. Ann Hematol 80:340-344, 2001
66. Tirelli U, Errante D, Dolcetti R, et al: Hodgkin's disease and human immunodeficiency virus infection: Clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 13:1758-1767, 1995
67. Dolcetti R, Boiocchi M, Gloghini A, et al: Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur J Cancer 37:1276-1287, 2001
68. Powles T, Bower M: HIV-associated Hodgkin's disease. Int J STD AIDS 11:492-494 2000
69. Levine AM, Li P, Cheung T, et al: Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: A prospective, multi-institutional AIDS Clinical Trials Group study (ACTG 149), J Acquir Immune Defic Syndr 24:444-450, 2000
70. Karcher DS: Clinically unsuspected Hodgkin disease presenting initially in the bone marrow of patients infected with the human immunodeficiency virus. Cancer 71:1235-1238, 1993
71. Errante D, Gabarre J, Ridolfo AL, et al: Hodgkin's disease in 35 patients with HIV infection: An experience with epirubicin, bleomycin. vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol 10:189-195, 1999
72. Vilchez RA, Finch CJ, Jorgensen JL, et al: The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. Medicine (Baltimore) 82:77-81, 2003